Abstract
Amyloid deposition is a vital biomarker in the process of Alzheimer’s diagnosis. Florbetapir PET scans can provide valuable imaging data to determine cortical amyloid quantities. However the process is labor and doctor intensive, requiring extremely specialized education and resources that may not be accessible to everyone, making the amyloid calculation process inefficient.
Deep learning is a rising tool in Alzheimer’s research which could be used to determine amyloid deposition. Using data from the Alzheimer’s Disease Neuroimaging Initiative, we identified 2980 patients with PET imaging, clinical, and genetic data. We tested various ResNet and EfficientNet convolutional neural networks and later combined them with Gradient Boosting Decision Tree algorithms to predict standardized uptake value ratio (SUVR) of amyloid in each patient session. We tried several configurations to find the best model tuning for regression-to-SUVR.
We found that the EfficientNetV2-Small architecture combined with a grid search-tuned Gradient Boosting Decision Tree with 3 axial input slices and clinical and genetic data achieved the lowest loss. Using the mean-absolute-error metric, the loss converged to an MAE of 0.0466, equating to 96.11% accuracy across the 596 patient test set.
We showed that this method is more consistent and accessible in comparison to human readers from previous studies, with lower margins of error and substantially faster calculation times. Deep learning algorithms could be used in hospitals and clinics with resource limitations for amyloid deposition, and shows promise for more imaging tasks as well.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Alzheimer's Disease Neuroimaging Initiative
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
sumaddurycollege2024{at}gmail.com (S.M.); krishdesaiedu{at}gmail.com (K.D.)
Data Availability
All data used is available online at: https://adni.loni.usc.edu/
